Guest Editorial How next generation sequencing is powering the shift to more accessible—and comprehensive—cancer care November 07, 2025Vol.51 No.41By Kathy Davy
Sponsored City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure November 07, 2025Vol.51 No.41By Ravi Salgia
NCINews Analysis Cancer centers adapt to life without site visits as NIH changes CCSG review October 31, 2025Vol.51 No.40By Paul Goldberg
Class action complaint alleging GRAIL insider fraud resubmitted after dismissal October 31, 2025Vol.51 No.40By Jacquelyn Cobb
Friends publishes three white papers ahead of annual meetingTopics: Clinical trials on rare cancers, combination drug trials, multi-regional studies October 31, 2025Vol.51 No.40By Sara Willa Ernst
Trials & Tribulations How GLP-1RA drugs are reshaping patient physiology and the future of oncology October 31, 2025Vol.51 No.40By Deborah Phippard
Regulatory News Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLCctMoniTR project aims to improve efficiency in development of intermediate endpoints October 24, 2025Vol.51 No.39By Jacquelyn Cobb
Duke brain cancer researcher Kyle Walsh named director of NIEHS October 24, 2025Vol.51 No.39By Paul Goldberg
GRAIL to use new study results to seek FDA approval of Galleri MCD test October 24, 2025Vol.51 No.39By Jacquelyn Cobb
Omar Abdel-Wahab, John Byrd, Lieping Chen, Robert Ferris, Wendy Garrett, Victor Velculescu are among new members of National Academy of Medicine October 24, 2025Vol.51 No.39By Paul Goldberg
